Uric Acid Elevation by Favipiravir, an Antiviral Drug

被引:64
作者
Mishima, Eikan [1 ]
Anzai, Naohiko [2 ]
Miyazaki, Mariko [1 ]
Abe, Takaaki [1 ,3 ,4 ]
机构
[1] Tohoku Univ, Div Nephrol Endocrinol & Vasc Med, Grad Sch Med, Sendai, Miyagi, Japan
[2] Chiba Univ, Dept Pharmacol, Grad Sch Med, Chiba, Chiba, Japan
[3] Tohoku Univ, Div Med Sci, Grad Sch Biomed Engn, Sendai, Miyagi, Japan
[4] Tohoku Univ, Dept Clin Biol & Hormonal Regulat, Grad Sch Med, Sendai, Miyagi, Japan
关键词
COVID-19; favipiravir; hyperuricemia; influenza; SARS-CoV-2; T-705;
D O I
10.1620/tjem.251.87
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In light of the recent pandemic, favipiravir (Avigan (R)), a purine nucleic acid analog and antiviral agent approved for use in influenza in Japan, is being studied for the treatment of coronavirus disease 2019 (COVID-19). Increase in blood uric acid level is a frequent side effect of favipiravir. Here, we discussed the mechanism of blood uric acid elevation during favipiravir treatment. Favipiravir is metabolized to an inactive metabolite M1 by aldehyde oxidase and xanthine oxidase, and excreted into urine. In the kidney, uric acid handling is regulated by the balance of reabsorption and tubular secretion in the proximal tubules. Favipiravir and M1 act as moderate inhibitors of organic anion transporter 1 and 3 (OAT1 and OAT3), which are involved in uric acid excretion in the kidney. In addition, M1 enhances uric acid reuptake via urate transporter 1 (URAT1) in the renal proximal tubules. Thus, favipiravir is thought to decrease uric acid excretion into urine, resulting in elevation of uric acid levels in blood. Elevated uric acid levels were returned to normal after discontinuation of favipiravir, and favipiravir is not used for long periods of time for the treatment of viral infection. Thus, the effect on blood uric acid levels was subclinical in most studies. Nevertheless, the adverse effect of favipiravir might be clinically important in patients with a history of gout, hyperuricemia, kidney function impairment (in which blood concentration of M1 increases), and where there is concomitant use of other drugs affecting blood uric acid elevation.
引用
收藏
页码:87 / 90
页数:4
相关论文
共 19 条
[1]   Drug-induced hyperuricaemia and gout [J].
Ben Salem, C. ;
Slim, Raoudha ;
Fathallah, Neila ;
Hmouda, Houssem .
RHEUMATOLOGY, 2017, 56 (05) :679-688
[2]  
Chen C., 2020, MEDRXIV, DOI [10.1101/2020.03.17.20 037432., DOI 10.1101/2020.03.17.20]
[3]   Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection [J].
Du Yin-Xiao ;
Chen Xiao-Ping .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (02) :242-247
[4]  
Fujita Health University Hospital, 2020, INT REP OBS STUD FAV
[5]   Mechanism of action of T-705 against influenza virus [J].
Furuta, Y ;
Takahashi, K ;
Kuno-Maekawa, M ;
Sangawa, H ;
Uehara, S ;
Kozaki, K ;
Nomura, N ;
Egawa, H ;
Shiraki, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :981-986
[6]   In vitro and in vivo activities of anti-influenza virus compound T-705 [J].
Furuta, Y ;
Takahashi, K ;
Fukuda, Y ;
Kuno, M ;
Kamiyama, T ;
Kozaki, K ;
Nomura, N ;
Egawa, H ;
Minami, S ;
Watanabe, Y ;
Narita, H ;
Shiraki, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) :977-981
[7]   Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase [J].
Furuta, Yousuke ;
Komeno, Takashi ;
Nakamura, Takaaki .
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES, 2017, 93 (07) :449-463
[8]   Advances in purine and pyrimidine metabolism in health and diseases [J].
Hirano, Michio ;
Peters, Godefridus J. .
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2016, 35 (10-12) :495-501
[9]   APICAL VOLTAGE-DRIVEN URATE EFFLUX TRANSPORTER NPT4 IN RENAL PROXIMAL TUBULE [J].
Jutabha, P. ;
Anzai, N. ;
Wempe, M. F. ;
Wakui, S. ;
Endou, H. ;
Sakurai, H. .
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2011, 30 (12) :1302-1311
[10]   Urinary excretion of uric acid is negatively associated with albuminuria in patients with chronic kidney disease: a cross-sectional study [J].
Li, Fengqin ;
Guo, Hui ;
Zou, Jianan ;
Chen, Weijun ;
Lu, Yijun ;
Zhang, Xiaoli ;
Fu, Chensheng ;
Xiao, Jing ;
Ye, Zhibin .
BMC NEPHROLOGY, 2018, 19